Skip to main content

8 Companion Diagnostic Developers Making a Mark | Clinical OMICs – Molecular Diagnostics in Personalized Medicine

By July 22, 2019News
dna-genetics-pixa

dna-genetics-pixa

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein overexpression in breast tumors of patients who may benefit from Herceptin (trastuzumab), a targeted therapeutic for certain types of breast cancer marketed by Genentech (now a member of the Roche Group).

{iframe}https://www.clinicalomics.com/magazine-editions/volume-6-issue-number-4-july-august-2019/8-companion-diagnostic-developers-making-a-mark/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.